MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors.
See the rest here:
Theratechnologies Appoints Two New Board Members
Related Post
- VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc... - October 18th, 2020
- Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients - October 18th, 2020
- Zogenix Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020 - October 18th, 2020
- CohBar to Present at the BIO-Europe Conference - October 18th, 2020
- Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th... - October 18th, 2020
- Valneva’s Chikungunya Vaccine Candidate Awarded EMA Prime Designation - October 18th, 2020
- Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) - October 18th, 2020
- Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial - October 18th, 2020
- MacroGenics Announces Flotetuzumab Publication in Blood Advances - October 18th, 2020
- Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia - October 18th, 2020
- Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) - October 18th, 2020
- ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions - October 18th, 2020
- MDxHealth announces listing of 20,162,924 existing shares on Euronext Brussels following Equity Investment by MVM Partners - October 18th, 2020
- Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen - October 17th, 2020
- First Patient Dosed in Phase II Trial to Treat Complications in COVID-19 - October 17th, 2020
- Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe - October 17th, 2020
- Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol - October 17th, 2020
- Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock - October 17th, 2020
- Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020 - October 17th, 2020
- Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome - October 17th, 2020
- Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination - October 17th, 2020
- CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis - October 17th, 2020
- SPACs Show Investors Faster, Simpler Way to Go Public - October 17th, 2020
- Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential - October 17th, 2020
- German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test - October 17th, 2020
- Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma - October 17th, 2020
- Stabilization measures taken - October 17th, 2020
- Coherus BioSciences Announces New Employment Inducement Grants - October 17th, 2020
- Biomerica Reports Fiscal 2021 1st Quarter Financial Results - October 17th, 2020
- Eton Pharmaceuticals Announces Closing of Public Offering - October 17th, 2020
- Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute... - October 17th, 2020
- Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange - October 17th, 2020
Recent Comments